Associated Papers
Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E.
Antonello ZA et al.
Oncotarget, 2017
29156680 (PubMed )
Supplement: oncotarget-08-84743-s005.xls › Sheet1
Select a paper to view details